Muscular Dystrophy News Home | Muscular Dystrophy News
WEB6 days ago · The U.S. Food and Drug Administration has granted rare pediatric disease designation to NS-050/NCNP-03, an exon-skipping Duchenne muscular dystrophy (DMD) treatment from NS Pharma. Treatments granted this designation are aimed at serious or life-threatening diseases affecting children and fewer than 200,000 U.S. patients.
MD and Your Heart Monitor: 6 Things I Wish I'd Known
WEBJan 23, 2018 · 1. Use lotion to remove adhesive. Lotion is the easiest way to remove the adhesive on your skin left from the stickers that connect to the electrodes. It is also the least irritating for your skin, especially if you have sensitive skin like me. Let the lotion sink into your skin before wiping of the adhesive with some tissue paper.
Ullrich Congenital Muscular Dystrophy (UCMD)
WEBUllrich congenital muscular dystrophy (UCMD) is a rare hereditary muscle condition that manifests at birth or a few months after birth. It belongs to a group of disorders called collagen type 6-related myopathies and characterized by abnormalities in collagen type 6, a major protein that supports skeletal muscles.. Causes. UCMD is caused by a mutation in one of three genes that provide ...
FDA approves oral givinostat, as Duvyzat, to treat Duchenne MD
WEBMar 22, 2024 · Therapy is 1st non-steroidal drug for patients with all genetic DMD variants. The U.S. Food and Drug Administration (FDA) has approved Italfarmaco’s givinostat, which will now be marketed as Duvyzat, as an oral suspension to treat people with Duchenne muscular dystrophy (DMD) ages 6 and older. Duvyzat becomes the …
Speech Therapy - Muscular Dystrophy News
WEBThe disease causes progressive weakness and wasting of muscles in different parts of the body, including the arms, legs, head, and neck. In some types of muscular dystrophy, weakness in the facial and oral muscles that control the use of the tongue, lips, soft palate, cheeks, and diaphragm results in problems with speech quality (dysarthria ...
Life Expectancy - Muscular Dystrophy News
WEBAll muscular dystrophies cause muscle weakness, but life expectancy can vary dramatically between types of muscular dystrophy. While some cases may be mild and progress slowly, others can cause severe muscle weakness and disability. Some people with muscular dystrophy may have reduced life expectancy while others have a normal lifespan.
HOPE-3 trial of DMD therapy CAP-1002 to continue as planned
WEBDec 12, 2023 · by Patricia Inácio, PhD December 12, 2023. The HOPE-3 clinical trial testing Capricor Therapeutics’ experimental cell therapy CAP-1002 for Duchenne muscular dystrophy (DMD) can continue as planned, the company announced. That’s the result of an interim futility analysis, which evaluates whether it is mathematically possible for a trial to ...
Bethlem Myopathy - Muscular Dystrophy News
WEBBethlem myopathy, named after the Dutch doctor who first described it in 1976, is a rare and progressive form of muscular dystrophy.The condition mainly affects skeletal muscles and, to an extent, connective tissues. Less than 100 cases of Bethlem myopathy have been reported in the literature, making it a very rare form of muscular dystrophy.. Bethlem myopathy has not been associated with ...
What Is Duchenne Muscular Dystrophy (DMD)?
WEBJan 19, 2022 · Duchenne muscular dystrophy is caused by mutations in the DMD gene, which provides cells with instructions for making a protein called dystrophin. Working in a complex with other proteins, dystrophin acts like a “shock absorber” in muscle cells, helping to protect the cells from wear-and-tear during the rigorous processes of muscle movements.
Approved Treatments for Muscular Dystrophy
WEBDuvyzat (givinostat) is an oral therapy approved in the U.S. for adults and children, ages 6 and older, with DMD. It aims to reduce inflammation and muscle loss in people with DMD, ultimately working to slow disease progression. Duvyzat is a small molecule designed to block enzymes of the histone deacetylase (HDAC) family, which are involved in ...